PAPER Shevah O, Laron Z
SEARCH RESULTS
330006 RESULTS
PAPER Fontana L, Partridge L, Longo VD
Extending healthy life span--from yeast to humans.
Science. 2010 Apr 16;328(5976):321-6. PubMed: 20395504PAPER Guevara-Aguirre J, Balasubramanian P, Guevara-Aguirre M, Wei M, Madia F, Cheng CW, Hwang D, Martin-Montalvo A, Saavedra J, Ingles S, de Cabo R, Cohen P, Longo VD
Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans.
Sci Transl Med. 2011 Feb 16;3(70):70ra13. PubMed: 21325617PAPER Büeler H, Aguzzi A, Sailer A, Greiner RA, Autenried P, Aguet M, Weissmann C
Mice devoid of PrP are resistant to scrapie.
Cell. 1993 Jul 2;73(7):1339-47. PubMed: 8100741PAPER Klöhn PC, Stoltze L, Flechsig E, Enari M, Weissmann C
A quantitative, highly sensitive cell-based infectivity assay for mouse scrapie prions.
Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11666-71. PubMed: 14504404PAPER Encalada SE, Szpankowski L, Xia CH, Goldstein LS
Stable kinesin and dynein assemblies drive the axonal transport of mammalian prion protein vesicles.
Cell. 2011 Feb 18;144(4):551-65. PubMed: 21335237PAPER Wickner RB
Prion diseases: Infectivity versus toxicity.
Nature. 2011 Feb 24;470(7335):470-1. PubMed: 21350474PAPER Sandberg MK, Al-Doujaily H, Sharps B, Clarke AR, Collinge J
Prion propagation and toxicity in vivo occur in two distinct mechanistic phases.
Nature. 2011 Feb 24;470(7335):540-2. PubMed: 21350487Emma Jones on α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
COMMENT Mollenhauer’s study benefits from examining three cohorts, including an autopsy-confirmed cohort with dementia with Lewy bodies (DLB) patients—a group often difficult to distinguish from Alzheimer’s disease (AD) by clinical testing. Measurements of severa
Emma Jones
King's College London
Metabolomics Comes of Age
SERIES Move over, genome, transcriptome, proteome. The latest ome aims to map every metabolite linked to human health and disease. Metabolomics, although still a nascent field, offers hope for biomarkers and treatments in neurodegenerative disease. The field
Metabolomics: Seeking Biomarkers for ALS, Parkinson’s, Huntington’s
RESEARCH NEWS 2011-03-01 Research News Metabolomics—the sum of every small molecule linked to health or illness—is a young field (see Part 1 and Part 2), but it has already given researchers studying Alzheimer’s disease plenty to think about (see Part 3). Scientists studying othe
In Prion Disease, Toxicity Comes After Infection
RESEARCH NEWS 2011-03-01 Research News Scientists’ view of amyloid’s role in Alzheimer’s disease has evolved from the view that large amyloid fibrils poison the brain to one primarily blaming soluble, oligomeric forms of Aβ. A similar evolution of thought may be on the horizon fo
Viva La Vida: New Clues to Living Long and Healthy
RESEARCH NEWS 2011-03-01 Research News For creatures ranging from yeast to worms to mice, impaired growth hormone signaling restricts size but brings big benefits—longer life, and protection from age-related disease. Now, a 22-year longitudinal study confirms that some of these a
PAPER Armon C
Smoking may be considered an established risk factor for sporadic ALS.
Neurology. 2009 Nov 17;73(20):1693-8. PubMed: 19917993Current Filters
No filters selected